- Home
- PBPB vs PRTA Comparison
PBPB vs PRTA Comparison
Compare PBPB & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBPB
- PRTA
- Stock Information
- Founded
- PBPB 1977
- PRTA 2012
- Country
- PBPB United States
- PRTA Ireland
- Employees
- PBPB N/A
- PRTA N/A
- Industry
- PBPB Restaurants
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- PBPB Consumer Discretionary
- PRTA Health Care
- Exchange
- PBPB Nasdaq
- PRTA Nasdaq
- Market Cap
- PBPB 515.2M
- PRTA 472.1M
- IPO Year
- PBPB 2013
- PRTA N/A
- Fundamental
- Price
- PBPB $17.09
- PRTA $10.35
- Analyst Decision
- PBPB Buy
- PRTA Buy
- Analyst Count
- PBPB 3
- PRTA 9
- Target Price
- PBPB $17.37
- PRTA $13.14
- AVG Volume (30 Days)
- PBPB 1.2M
- PRTA 733.5K
- Earning Date
- PBPB 11-06-2025
- PRTA 11-11-2025
- Dividend Yield
- PBPB N/A
- PRTA N/A
- EPS Growth
- PBPB N/A
- PRTA N/A
- EPS
- PBPB 0.35
- PRTA N/A
- Revenue
- PBPB $469,138,000.00
- PRTA $10,341,000.00
- Revenue This Year
- PBPB $5.24
- PRTA N/A
- Revenue Next Year
- PBPB $4.70
- PRTA $602.32
- P/E Ratio
- PBPB $49.33
- PRTA N/A
- Revenue Growth
- PBPB N/A
- PRTA N/A
- 52 Week Low
- PBPB $7.27
- PRTA $4.32
- 52 Week High
- PBPB $17.10
- PRTA $18.88
- Technical
- Relative Strength Index (RSI)
- PBPB 81.58
- PRTA 78.54
- Support Level
- PBPB $17.05
- PRTA $9.58
- Resistance Level
- PBPB $17.07
- PRTA $10.37
- Average True Range (ATR)
- PBPB 0.02
- PRTA 0.44
- MACD
- PBPB -0.15
- PRTA 0.08
- Stochastic Oscillator
- PBPB 87.50
- PRTA 92.21
About PBPB Potbelly Corporation
Potbelly Corp owns and franchises hundreds of limited-service restaurants specializing in sandwiches and salads, shakes. The menu includes toasty sandwiches, signature salads, soups, chili, sides, desserts, and, in breakfast locations it serves breakfast sandwiches and steel-cut oatmeal. majority of its locations are company-owned and located in the United States, with Illinois and Texas housing far more locations than any other state. The company has franchise partners in a number of countries. Excluding the United States, its franchises are in the Middle East.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.